BRIEF—Eurofins Genomics US opens oligonucleotide manufacturing facility

An oligonucleotide manufacturing facility has been opened by Eurofins Genomics US.

The expansion significantly increases manufacturing capacity and capabilities, allowing the Eurofins Scientific subsidiary to meet the ever-growing global demand for GMP-grade and research use oligonucleotides.

This facility is designed to an environment for the production of synthetic DNA and RNA that ensures the highest standards of quality, safety, and efficiency.

Sumit Gupta, president of Eurofins Genomics US, said: “This marks a significant milestone in our commitment to excellence and innovation in genomics.”